MEDICINA
Departamento
University of Lille Nord de France
Lila, FranciaPublicaciones en colaboración con investigadores/as de University of Lille Nord de France (27)
2024
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica, Vol. 108, Núm. 11, pp. 2894-2912
-
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Expert Review of Hematology, Vol. 16, Núm. 11, pp. 835-847
2022
-
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8
-
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
2021
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Annals of Oncology, Vol. 32, Núm. 3, pp. 309-322
-
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Leukemia, Vol. 35, Núm. 1, pp. 31-44
-
ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement
Journal of the American College of Cardiology, Vol. 77, Núm. 17, pp. 2187-2199
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 714-720
-
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 681-694